Skip to content

Editors

Harry Cassin
Publisher and Editor

Andy Spalding
Senior Editor

Jessica Tillipman
Senior Editor

Bill Steinman
Senior Editor

Richard L. Cassin
Editor at Large

Elizabeth K. Spahn
Editor Emeritus

Cody Worthington
Contributing Editor

Julie DiMauro
Contributing Editor

Thomas Fox
Contributing Editor

Marc Alain Bohn
Contributing Editor

Bill Waite
Contributing Editor

Shruti J. Shah
Contributing Editor

Russell A. Stamets
Contributing Editor

Richard Bistrong
Contributing Editor

Eric Carlson
Contributing Editor

Second subpoena in SciClone China probe

SciClone Pharmaceuticals Inc. said Friday that an investigation launched three years ago into possible FCPA violations in China is ongoing and the SEC has issued a new subpoena focused on ‘sales and marketing expenses’ by its NovaMed unit there.… Continue Reading

Docs collect billions for drug promos

ProPublica ran an exposé this week about big bucks for doctors who promote products for drug companies.

A Nashville psychiatrist led the pack, earning more than $1 million during the past four years for promotional talks and consulting for seven drug companies.… Continue Reading

Fox’s Top Ten For 2011, Corporate Division

As December is a time for reflection on the past twelve months, I have been considering the FCPA Enforcement Action year.

I submit for your consideration my Top 10 FCPA Enforcement Actions for 2011 in the Corporate Division.… Continue Reading

Is Pharma Under Fire In Indonesia?

As we said, two FBI agents at an international law enforcement conference last week said several U.S. public companies are being investigated for bribery in Indonesia.

The agents wouldn’t name names.… Continue Reading

The Novartis Speakers Bureau

Last week, Novartis agreed to pay a $185 million criminal fine for off-label marketing of the epilepsy drug Trileptal, and $237.5 million to resolve civil allegations over kickbacks paid to doctors to prescribe Trileptal and five other drugs.… Continue Reading

Watching For Whistleblowers

In its quarterly report released August 9, SciClone Pharmaceuticals, Inc. said it received an SEC subpoena and a letter from the DOJ investigating the “sale, licensing and marketing of its products in foreign countries, including China.”… Continue Reading